Intellia Therapeutics, Inc. (NTLA): Price and Financial Metrics
Intellia Therapeutics, Inc. (NTLA)
Today's Latest Price: $23.94 USD
Updated Oct 30 4:00pm
Add NTLA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
NTLA Stock Summary
- Of note is the ratio of Intellia Therapeutics Inc's sales and general administrative expense to its total operating expenses; just 11.89% of US stocks have a lower such ratio.
- With a price/sales ratio of 27.72, Intellia Therapeutics Inc has a higher such ratio than 94.08% of stocks in our set.
- As for revenue growth, note that NTLA's revenue has grown 37.71% over the past 12 months; that beats the revenue growth of 87.21% of US companies in our set.
- Stocks that are quantitatively similar to NTLA, based on their financial statements, market capitalization, and price volatility, are KALV, VBLT, RCUS, FULC, and NXTC.
- NTLA's SEC filings can be seen here. And to visit Intellia Therapeutics Inc's official web site, go to www.intelliatx.com.
NTLA Stock Price Chart Interactive Chart >
NTLA Price/Volume Stats
| Current price | $23.94 | 52-week high | $27.07 |
| Prev. close | $24.95 | 52-week low | $9.18 |
| Day low | $23.49 | Volume | 535,200 |
| Day high | $24.96 | Avg. volume | 857,422 |
| 50-day MA | $22.11 | Dividend yield | N/A |
| 200-day MA | $18.01 | Market Cap | 1.41B |
Intellia Therapeutics, Inc. (NTLA) Company Bio
Intellia Therapeutics a gene editing company, develops therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Loading social stream, please wait...